GleamWall
中文EN

EQ Equillium, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1746466 · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY13.9%
TTM net income YoY39.5%
TTM EPS YoY39.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-20.1%
Net margin-19.6%
FCF margin-46.5%
EBITDA margin-19.8%

Returns

ROE-38.8%
ROA-21.2%
ROIC (approx.)-3,923.0%
Asset turnover1.08x

Leverage & solvency

Liabilities / assets25.6%
Debt / equity0.00x
Current ratio3.93x
Interest coverage—

Cash quality & payout

Operating cash flow / net income2.36x
Accruals ratio28.8%
Payout ratio—
Capex / revenue0.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue—$41.09M
R&D expense$12.84M$37.43M
SG&A expense$10.79M$11.94M
Operating income-$23.63M-$8.27M
Pretax income-$22.40M-$7.71M
Income tax$0$361,000
Net income-$22.40M-$8.07M
EBITDA-$23.52M-$8.13M
EPS (basic)-0.39-0.23
EPS (diluted)-0.39-0.23
Weighted avg. shares (diluted)57.30M35.36M
Balance sheet
Cash & equivalents$30.28M$18.09M
Short-term investments—$4.49M
Receivables—$0
Current assets$31.04M$24.98M
PP&E, net$164,000$262,000
Total assets$31.89M$25.60M
Current liabilities$2.93M$6.36M
Total liabilities$3.29M$6.54M
Shareholders' equity$28.60M$19.06M
Shares outstanding61.46M35.56M
Cash flow statement
Operating cash flow-$22.75M-$19.03M
Capital expenditure$48,000$85,000
Free cash flow-$22.79M-$19.11M
Investing cash flow$4.46M$13.81M
Financing cash flow$30.43M$164,000
Depreciation & amortization$116,000$137,000
Stock-based compensation$2.32M$3.75M

Free plan shows the latest 2 periods; Pro shows all 8 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.